Quick Answer
VitaNova Life Sciences Corp reported Operating Income Loss of $1.21 million for the year ending 2025.
- VitaNova Life Sciences Corp showed an increase of +487.6% in Operating Income Loss from 2024 to 2025.
- This data is from VitaNova Life Sciences Corp's annual report (Form 10-K), filed with the SEC on July 24, 2025.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: $5.8 thousand | Q3 2018: -$15.8 thousand | Q4 2018: -$8.1 thousand | Q1 2019: -$36.7 thousand | Q3 2019: -$19.9 thousand | Q4 2019: -$19.5 thousand | Q1 2020: -$6.6 thousand | Q3 2020: -$11.2 thousand | Q4 2020: -$12.4 thousand | Q1 2021: -$2.9 thousand | Q3 2021: -$10.5 thousand | Q4 2021: -$30.0 thousand | Q3 2022: $2.1 thousand | Q3 2023: -$24.2 thousand | Q4 2023: -$8.8 thousand | Q1 2024: $5.9 thousand | Q4 2024: $62.6 thousand | Q1 2025: $108.9 thousand | Q4 2025: $99.2 thousand | Q1 2026: $46.7 thousand.
- Over the full 8 years of available data (2018 to 2025), VitaNova Life Sciences Corp's Operating Income Loss has grown by 2,583.7%.
- Historical annual values: Fiscal year 2025: $1.21 million | Fiscal year 2024: $205.6 thousand | Fiscal year 2023: -$24.2 thousand | Fiscal year 2022: -$13.4 thousand | Fiscal year 2021: -$52.1 thousand | Fiscal year 2020: -$72.3 thousand | Fiscal year 2019: -$71.8 thousand | Fiscal year 2018: -$48.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: